Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Prince Harry embarks on a new courtroom battle against British tabloids in his case against Rupert Murdoch’s News Group ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...